All In Biotech

NDA 018934 · Chartwell Rx

Methyldopa

Methyldopa · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Aug 5, 1998 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jun 29, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

10 Phase 3, 2 recruiting

FAERS reports

4,936

4,615 serious, 231 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2025.

INDICATION AND USAGE Hypertension.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 29, 1984 Original approval
2 products under this application
  • METHYLDOPA · METHYLDOPA 250MG · TABLET, ORAL · Discontinued
  • METHYLDOPA · METHYLDOPA 500MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Methyldopa" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy1,364
  • premature baby930
  • maternal exposure during pregnancy838
  • exposure during pregnancy698
  • premature delivery584
  • low birth weight baby389
  • drug ineffective268
  • hypertension259
  • off label use231
  • foetal growth restriction216
  • pre-eclampsia208
  • atrial septal defect196

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200571
200663
200760
200899
2009127
2010112
2011161
2012161
2013166
2014253
2015198
2016219
2017245
2018468
2019431
2020393
2021346
2022329
2023257
2024305
2025199
2026236

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 484 on PubMed

Sponsor: Chartwell Rx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.